Perindopril angiotensin-Converting Enzyme Inhibitors

Description Results

NYHA class improvement 2.03 [1.24; 3.32]

all cause death or hospitalisation 0.00 [0.00; NaN]

Hospitalisation 0.64 [0.43; 0.97]

Death 0.90 [0.47; 1.71]

Long term death (1 year) 0.90 [0.47; 1.71]

all cause death or hospitalisation 0.69 [0.47; 1.02]

perindopril, 2 mg once daily (n=61)

vs.

placebo (n=64)

double blind

Sample size: 61/64

Primary endpoint:

FU duration: 3-month

perindopril, 4 mg/day (n=424)

vs.

placebo (n=426)

double blind

Parallel groups

Sample size: 424/426

Primary endpoint: all-cause mortality and unplanned heart failure related hospitalization

FU duration: 26.2 months (range 12-54.2m)

Hospitalisation 0.64 [0.43; 0.97]

Death 0.90 [0.47; 1.71]

Long term death (1 year) 0.90 [0.47; 1.71]

all cause death or hospitalisation 0.69 [0.47; 1.02]

perindopril, 4 mg/day (n=424)

vs.

placebo (n=426)

double blind

Parallel groups

Sample size: 424/426

Primary endpoint: all-cause mortality and unplanned heart failure related hospitalization

FU duration: 26.2 months (range 12-54.2m)

Crit principaux 0.81 [0.72; 0.91]

EUROPA endpoint 0.81 [0.72; 0.91]

Ev. coronariens 0.77 [0.66; 0.88]

Infarctus non mortel 0.78 [0.67; 0.90]

Ev. cardiovasculaires 0.81 [0.72; 0.91]

Toux 5.06 [3.47; 7.38]

hypotension 3.53 [2.06; 6.04]

Arrêt pour effet secondaire 1.10 [1.03; 1.17]

Insuffisance rénale 1.25 [0.65; 2.41]

Mortalité totale 0.89 [0.78; 1.02]

Décès cardiovasculaires 0.86 [0.72; 1.03]

revascularisation 0.96 [0.86; 1.07]

AVC mortels et non mortels 0.96 [0.73; 1.26]

perindopril 8 mg once daily (n=6110)

vs.

placebo (n=6108)

double blind

Parallel groups

Sample size: 6110/6108

Primary endpoint: cardiovascular death, myocardial infarction, or cardiac arrest

FU duration: 4.2y